intrexon

#Precigen completes series of transactions to solidify healthcare focus. Name changes to @Precigen from @Intrexon and ticker symbol to @Nasdaq: $PGEN #Maryland #biopharma #GeneTherapy #CellTherapy #Immunotherapy prn.to/2SbVCiI

Triple-Gene to highlight its investigational #genetherapy in Phase 1 for treatment of #heartfailure at #BiotechShowcase TODAY January 15th at 11:30am PT in Franciscan B at the Hilton San Francisco Union Square $XON #Precigen #cardiovasculardisease #JPMHC20 #JPM2020 #JPMorgan2020

At #JPMHC20? Listen to Dr. Helen Sabzevari, President & CEO of @Precigen, at 5pm PT in California West present on #Precigen progress and 2020 look ahead OR watch live webcast here: ow.ly/2ndc50xVC11 $XON #JPM2020 #JPMorgan2020 #GeneTherapy #CellTherapy #Immunotherapy

Join Dr. Helen Sabzevari, President and CEO of Precigen, at #JPM20 for her presentation on Precigen’s progress and a 2020 look ahead. #GeneTherapy #CellTherapy #Immunotherapy #Biotech #Maryland $XON bit.ly/2QMuOWK

Triple-Gene to highlight advantages of its multigenic approach for treatment of #heartfailure at #BiotechShowcase on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square. Read more here: ow.ly/Aof250xR5IF #cardiovasculardisease #genetherapy $XON

Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. bizjournals.com/washington/new…

#Precigen receives first regulatory designation for PRGN-3006 UltraCAR-T #OrphanDrugDesignation #immunotherapy #biotech prn.to/2ZThUcc

$XON To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To @Precigen To Reflect Healthcare Focus. Read more here: ow.ly/z7hz50xLsQx #immunotherapy #genetherapy #Maryland #biotech

#Precigen’s Tim Chan to present preclinical data from PRGN-3006 UltraCAR-T at #ASH2019 in Orlando, FL #CellTherapy #AML #MDS #BloodCancer #Immunotherapy bit.ly/2KFJm78

Dr. Helen Sabzevari, President of #Precigen, will speak at the upcoming World Vaccine & Immunotherapy Congress in San Francisco. Join us! bit.ly/2OFw2C3 #immunotherapy #UltraCAR-T #oncology #CellTherapy #MarylandInnovates $XON

Great news from our partners at #Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for #oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our #ActoBiotics® platform and licensed to Oragenics. More: actobio.com

$XON subsidiary Triple-Gene presented preliminary phase 1 trial data of investigational multigenic therapeutic candidate INXN 4001 for treatment of #heartfailure at #AHA19. Discover more: ow.ly/M0x850xdDMp and ow.ly/l2AY50xdDMq #cardiovasculardisease #genetherapy

Discover more about Triple-Gene’s approach to address #heartfailure: @physicianswkly highlights “The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure” ow.ly/OKbl50xc7WO $XON #cardiovasculardisease #genetherapy

Intrexon Reports Third Quarter Financial Results: ow.ly/I12g50x8EMd. @Precigen to host conference call today at 11am ET to provide Precigen business and pipeline updates. Register for call here: ow.ly/uNn050x8EMb $XON #immunotherapy #genetherapy #celltherapy

Intrexon subsidiary Triple-Gene announces completion of dosing in Phase 1 trial of INXN-4001, first multigenic investigational #genetherapy candidate for treatment of #heartfailure. Learn more here: ow.ly/rDyV50x4Cwt $XON #cardiovasculardisease

$XON to Announce Third Quarter Financial Results on Nov 12th. @Precigen to host conference call that day at 11am ET to provide Precigen business and pipeline updates. To learn more and register, click here: ow.ly/Lw4750x1N4Q #immunotherapy #genetherapy #celltherapy

At #BIOInvestorForum? Don’t miss #ActoBio Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform today Wednesday October 23 @ 9:15 AM PT. Read more: actobio.com or follow us on LinkedIn or Twitter @ActobioT #bif19 #biotech

At #SynBioBeta? Don't miss #ActoBio Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: actobio.com or follow on Twitter @ActobioT or LinkedIn. #actobiotics #healthcare #biotech

David Witte formerly of @IHSMarkit to lead MBP Titan LLC, standalone subsidiary company of Intrexon comprising Intrexon’s #Methane #Bioconversion Platform. Discover more: ow.ly/3ewV50wrZUP. $XON #energy #bioengineering #betterDNA

If you're attending #SynBioBeta2019 don't miss #ActoBio Therapeutics™ CEO Pieter Rottiers' overview of the innovative #ActoBiotics® platform and its applications on October 1. Read more: actobio.com, follow us on Linkedin or Twitter @ActobioT #biotech #immunology